Federal prosecutors have charged three people with billing Medicare more than $118 million for wound-graft procedures that were medically unnecessary or, in some cases, never performed at all. Leigh Tesar, Walter Presha Jr., and Koby Evans face health care fraud and conspiracy counts in an indictment filed in the Middle District of Florida, Case No. 8:26-cr-00216-MSS-LSG. The case is part of a national enforcement sweep that charged 455 defendants in connection with over $6.5 billion in alleged fraud, and it arrives just as new Medicare coverage rules tighten the requirements for skin-substitute billing.
Why the $118 million wound-graft case signals a broader crackdown
The charges against Tesar, Presha, and Evans are not isolated. Their case was announced as part of a national health care fraud takedown that spanned multiple federal districts and targeted schemes across several medical specialties. According to the Justice Department, the nationwide sweep charged hundreds of defendants with schemes involving telemedicine, genetic testing, prescription drugs, and other high-cost services. Skin-substitute and wound-allograft billing has drawn particular scrutiny because of how fast spending in the category has grown and how easily the procedures can be misused to generate large Medicare claims.
The broader initiative is described in a Justice Department summary of the takedown, which links the wound-graft case to a coordinated effort by the Criminal Division’s Fraud Section, U.S. Attorneys’ Offices, and investigative agencies including HHS-OIG and the FBI. Officials have emphasized that fraud involving vulnerable patients and medically unnecessary services is a priority because it inflates costs for the Medicare program and can expose beneficiaries to harm.
At the same time, CMS has moved to restrict when these products qualify for reimbursement. A local coverage determination, LCD L36690, now sets specific clinical criteria for wound application of cellular and tissue-based products on lower extremities. The delayed effective date for these LCD changes was set at January 1, 2026, according to a CMS statement on the policy. Billing and coding article A56696 spells out documentation requirements, including consistency between the number of units billed and the wound-size measurements in a patient’s medical record. Together, these policy changes and the criminal prosecution create dual pressure on providers: tighter rules for legitimate claims and steeper consequences for fraudulent ones. The practical effect is likely to be a measurable drop in Medicare Part B skin-substitute billing volume over the next year, driven not by fewer patients needing wound care but by stricter gatekeeping on which procedures get paid.
What the indictment alleges Tesar, Presha, and Evans did
The federal indictment document lays out several categories of alleged misconduct. Prosecutors say the defendants submitted Medicare claims for skin allografts applied to patients whose wounds were infected, a clinical scenario where grafts are generally not indicated. Other claims allegedly involved terminally ill patients or situations in which the graft product was never actually applied to the patient’s wound. The charges include health care fraud, conspiracy to commit health care fraud, and anti-kickback violations tied to the referral of patients for the graft procedures.
According to the charging document, the defendants are accused of using their roles in wound-care clinics to generate high-dollar claims by repeatedly billing for graft applications on the same patients, regardless of whether the treatment was clinically appropriate. In some instances, prosecutors allege that medical records were falsified or exaggerated to justify additional applications or larger quantities of product. The indictment also describes alleged kickback arrangements in which payments or other benefits were provided in exchange for patient referrals and orders for specific wound-graft products, conduct that is prohibited when federal health care programs are involved.
The financial scale is significant. At $118 million in alleged fraudulent billing, this single case accounts for a notable share of the national takedown’s $6.5 billion total. Federal officials have linked the growth in skin-substitute spending to higher overall Medicare Part B costs and projected premium pressure for beneficiaries, arguing that unchecked overutilization in niche product categories can ripple through the program’s finances. By bringing criminal charges in a high-profile case while simultaneously tightening coverage rules, regulators are signaling that both front-end utilization controls and back-end enforcement will be used to curb abuse.
For legitimate providers, the message is twofold. First, wound-care practices that rely heavily on skin substitutes will need to ensure that documentation clearly supports medical necessity under the new LCD criteria, including accurate wound measurements, infection status, and evidence of prior conservative treatment. Second, any financial relationships with product manufacturers, distributors, or referral sources must be structured to comply with anti-kickback laws, with particular care around consulting agreements, marketing support, and volume-based incentives.
For patients, the crackdown may mean closer review of claims and, in some cases, delays or denials when documentation does not meet Medicare’s tightened standards. But officials contend that the ultimate goal is to protect beneficiaries from unnecessary or risky procedures while preserving access to advanced wound care when it is truly needed. As the Tesar, Presha, and Evans case moves through the courts, it will serve as an early test of how criminal enforcement and policy reform interact in one of Medicare’s fastest-growing and most controversial spending categories.
Free tool for readers: Curious where your retirement stands on a 0–100 scale? You can get your free Retirement Safety Score in about five minutes — no account, no bank details, just your number and a few steps to improve it.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
